Evidence map›Paper›PMID 31055607›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2019

Chrysophanol, an anthraquinone from AST2017-01, possesses the anti-proliferative effect through increasing p53 protein levels in human mast cells.

Na-Ra Han, Hee-Yun Kim, Soonsik Kang, Mi Hye Kim, Kyoung Wan Yoon, Phil-Dong Moon, Hyung-Min Kim, Hyun-Ja Jeong

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Na-Ra HanDepartment of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea.
Hee-Yun KimDepartment of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea.
Soonsik KangDepartment of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Mi Hye KimDepartment of Food and Nutrition, Hoseo University, Asan, Chungnam, 31499, Republic of Korea.
Kyoung Wan YoonDepartment of Biotechnology, Hoseo University, Asan, Chungnam, 31499, Republic of Korea.
Phil-Dong MoonDepartment of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea.
Hyung-Min KimDepartment of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea. hmkim@khu.ac.kr.
Hyun-Ja JeongDivision of Food and Pharmaceutical Engineering, Biochip Research Center, Hoseo University, Asan, Chungnam, 31499, Republic of Korea. hjjeong@hoseo.edu.
Kyung Hee University · KRHoseo University · KR

Funding

This work was supported by Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through High Value-added Food Technology Development Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA) (116169-3)
6 · The paper itself

Abstract

objectiveNatural products are well known as the source of drugs in the treatment of allergic inflammation. Chrysophanol, an anthraquinone from the AST2017-01 extract, showed a beneficial anti-inflammatory effect on activated human mast cells in our previous study. However, a regulatory effect of AST2017-01 and chrysophanol on mast cell proliferation induced by thymic stromal lymphopoietin (TSLP) remains unclear. The present study determined the anti-proliferative effect and the fundamental mechanism of AST2017-01 and chrysophanol in mast cells.

methodsWe evaluated an anti-proliferative effect of AST2017-01 and chrysophanol in TSLP-stimulated human mast cell line, HMC-1.

resultsWithout cytotoxicity, AST2017-01 and chrysophanol decreased mast cells growth and Ki67 mRNA expression increased by TSLP. AST2017-01 and chrysophanol enhanced expressions of p53 and Bax, whereas inhibited expression of Bcl-2. AST2017-01 and chrysophanol restored caspase-3 activity which was decreased by TSLP. AST2017-01 and chrysophanol suppressed expressions of murine double minute-2 protein and phosphorylated-signal transducer and activator of transcription six which are associated with the regulation of p53 protein. AST2017-01 and chrysophanol decreased levels of interleukin (IL)-13, IL-6, and tumor necrosis factor-α. Moreover, AST2017-01 and chrysophanol reduced mRNA expressions of TSLP receptor and IL-7 receptor α.

conclusionsTherefore, this study proposes that AST2017-01 and chrysophanol may be promising candidates for the development of potent anti-inflammatory or health functional foods.

Indexed as

AnthraquinonesAnti-Inflammatory AgentsCaspase 3Cell LineCell ProliferationComplex MixturesCordycepsCytokinesHumansMast CellsProto-Oncogene Proteins c-mdm2RumexSTAT6 Transcription FactorThymic Stromal LymphopoietinTumor Suppressor Protein p53AnthraquinonesAnti-Inflammatory AgentsCaspase 3chrysophanic acidComplex MixturesCytokinesMDM2 protein, humanProto-Oncogene Proteins c-mdm2STAT6 protein, humanSTAT6 Transcription FactorThymic Stromal LymphopoietinTP53 protein, humanTumor Suppressor Protein p53ChrysophanolMast cellMurine double minute-2p53Thymic stromal lymphopoietin

Identifiers

PMID31055607
OpenAlexW2942748095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.